Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Syndeio Biosciences, Inc
- Study ID
- NCT06547489
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 64 Years
- Healthy Volunteers
- Not accepted
Interventions
- Zelquistinel — DRUGZelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
Study Details
The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no zelquistinel)? What medical problems are observed in participants who take zelquistinel? Participants will take one tablet of zelquistinel or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.
Key Dates
- Start date
- Feb 3, 2025
- Status verified
- May 2026
- Primary completion
- Sep 30, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 164 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: zelquistinel (GATE-251)zelquistinel (GATE-251) will be administered as a single 10 mg oral tablet one time each week for 6 weeks.
- Placebo Comparator: PlaceboPlacebo tablet identical in appearance to the experimental treatment tablet, administered as as a single oral tablet one time each week for 6 weeks.
Primary Outcome Measure
Change in the Hamilton Depression Rating Scale-17 (HDRS-17) score compared to placebo [ Time Frame: Change in score from predose baseline to end of week 6 ]
Central Contacts
- Karen Raudibaugh781-786-1545
- Kelly Kosko215-510-6405
Locations (34)
Find similar trials in Birmingham, AL
Related Studies
- DBS for DepressionRecruiting · Baylor College of Medicine · Dallas, Texas
- Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar DisorderEARLY_PHASE1 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts
- A Phase I/II Study of PDC-1421 for Treating Depression in Cancer PatientsPHASE1/PHASE2 · Not Yet Recruiting · BioLite, Inc. · Los Angeles, California
- Mechanisms of Rumination Change in Adolescent DepressionRecruiting · Ohio State University · Columbus, Ohio